A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers.

ABSTRACT:

Background

Treatment options for the Triple-Negative Breast Cancer (TNBC) subtype remain limited and the outcome for patients with advanced TNBC is very poor. The standard of care is chemotherapy, but approximately 50% of tumors develop resistance.

Methods

We performed gene expression profiling of 58 TNBC tumor samples by microarray, comparing chemosensitive with chemoresistant tumors, which revealed that one of the top upregulated genes was TGFβ2. A connectivity mapping bioinformatics analysis predicted that the SRC inhibitor Dasatinib was a potential pharmacological inhibitor of chemoresistant TNBCs. Claudin-low TNBC cell lines were selected to represent poor-outcome, chemoresistant TNBC, for in vitro experiments and in vivo models.

Results

In vitro, we identified a

SUBMITTER: Angel CZ 

PROVIDER: S-EPMC11426005 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature